CuraGen (CRGN) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (384)	4/5/2005 1:05:08 PM
From: Jim Oravetz	Read Replies (1) of 478

Jonathan Rothberg To Step Down As CEO Of CuraGen DOW JONES NEWSWIRES April 5, 2005 6:30 a.m. NEW HAVEN, Conn. -- Curagen Corp. (CRGN) founder, Jonathan Rothberg, plans to step down as chief executive when his replacement is named. Company officials weren't immediately available to explain why Rothberg is relinquishing the chief executive post or to disclose if he will remain with the company in another capacity. In a press release Tuesday, the biotechnology concern said it wants to hire a chief executive to turn Curagen's pipeline of treatment candidates into drugs. The company develops therapies for the areas of oncology, inflammatory diseases and diabetes. Director Patrick Zenner will chair the committee searching for a new chief executive. Shares of Curagen hit a year low of $3.75 before ending Monday's session at $3.90 on Nasdaq. The company's shares reached a year high of $7.95 on Dec. 2. Company Web site: curagen.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next